$32.01
4.79% yesterday
Nasdaq, Jun 11, 10:00 pm CET
ISIN
US05370A1088
Symbol
RNA
Sector
Industry

Avidity Biosciences Inc Stock price

$32.01
+2.68 9.14% 1M
-3.57 10.03% 6M
+2.93 10.08% YTD
+3.09 10.68% 1Y
+3.51 12.32% 5Y
+3.51 12.32% 10Y
+3.51 12.32% 20Y
Nasdaq, Closing price Wed, Jun 11 2025
-1.61 4.79%
ISIN
US05370A1088
Symbol
RNA
Sector
Industry

Key metrics

Market capitalization $3.86b
Enterprise Value $2.48b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 277.55
P/S ratio (TTM) P/S ratio 432.08
P/B ratio (TTM) P/B ratio 2.90
Revenue growth (TTM) Revenue growth -17.92%
Revenue (TTM) Revenue $8.93m
EBIT (operating result TTM) EBIT $-433.27m
Free Cash Flow (TTM) Free Cash Flow $-365.22m
Cash position $1.38b
EPS (TTM) EPS $-2.85
P/E forward negative
P/S forward 577.08
EV/Sales forward 370.70
Short interest 13.55%
Show more

Is Avidity Biosciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,842 stocks worldwide.

Avidity Biosciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Avidity Biosciences Inc forecast:

15x Buy
100%

Analyst Opinions

15 Analysts have issued a Avidity Biosciences Inc forecast:

Buy
100%

Financial data from Avidity Biosciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
8.93 8.93
18% 18%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 106 106
89% 89%
1,186%
- Research and Development Expense 336 336
60% 60%
3,765%
-430 -430
70% 70%
-4,819%
- Depreciation and Amortization 2.92 2.92
24% 24%
33%
EBIT (Operating Income) EBIT -433 -433
70% 70%
-4,852%
Net Profit -369 -369
61% 61%
-4,135%

In millions USD.

Don't miss a Thing! We will send you all news about Avidity Biosciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Avidity Biosciences Inc Stock News

Neutral
PRNewsWire
about 22 hours ago
-- FDA alignment on accelerated and full approval pathways for delpacibart braxlosiran  (del-brax) in facioscapulohumeral muscular dystrophy (FSHD) -- -- Jeffrey M. Statland, M.D.
Neutral
PRNewsWire
3 days ago
-- Unprecedented data from FORTITUDE™ dose escalation cohorts for del-brax treated participants, compared to placebo, demonstrate improvement in function, strength and PROs as well as rapid and significant reduction in biomarkers -- -- Data support planned accelerated approval BLA submission in H2 2026 -- -- Data being presented at the 32nd Annual FSHD Society International Research Congress (I...
Neutral
PRNewsWire
3 days ago
-- Planning accelerated approval BLA submission in H2 2026, following topline data fromFORTITUDE™ biomarker cohort in Q2 2026 -- -- Initiated global, confirmatory Phase 3 FORWARD ™ study of del-brax 2mg/kg every six weeks -- -- Investor and analyst webcast event today, Monday, June 9, 2025 at 8 a.m. ET -- SAN DIEGO , June 9, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopha...
More Avidity Biosciences Inc News

Company Profile

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) designed to treat a range of serious diseases. The company's lead product candidate is AOC 1001 for treatment of myotonic dystrophy type 1; and four other muscle programs, which focus on the treatment of muscle atrophy, duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. It utilizes its proprietary AOC platform to design, engineer, and develop therapeutics that combine tissue selectivity of monoclonal antibodies and precision of oligonucleotide therapies to access previously undruggable tissue and cell types, and target underlying genetic drivers of diseases. The company also has development programs that focuses on immune and other cell types. Avidity Biosciences, Inc. was founded in 2012 and is based in La Jolla, California.

Head office United States
CEO Sarah Boyce
Employees 391
Founded 2012
Website www.aviditybiosciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today